We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
U.S. Pharmaceutical Preparation Market. Analysis And Forecast to 2030
Report Update: Feb 1, 2025

U.S. Pharmaceutical Preparation Market. Analysis And Forecast to 2030

Single report
Sent by email within 24h (Mon-Fri)
What's the difference?
Subscription
Online access and download
from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing
Jan 15, 2025

Bristol Myers Squibb's Cobenfy Revolutionizing Alzheimer's Treatment

Bristol Myers Squibb has identified Alzheimer's disease as the primary market for its newly approved schizophrenia drug, Cobenfy, which is anticipated to generate significant revenue. According to CNBC, the pharmaceutical giant is optimistic that Cobenfy will capture a sector ripe for both innovation and economic potential.

Company executives disclosed that every treatment application under study for Cobenfy possesses multi-billion-dollar potential, including conditions such as Alzheimer's disease psychosis, agitation, cognition, bipolar disease, and autism. David Elkins, CFO of Bristol Myers Squibb, shared at the JPMorgan Health Care Conference that Alzheimer's represents the "really large market here." In the United States, nearly 6 million individuals suffer from Alzheimer's, with approximately half experiencing psychosis accompanied by hallucinations and delusions.

As opposed to traditional atypical antipsychotics, which carry an increased risk of mortality, Cobenfy is distinct in that it does not elevate this risk, an assertion by Bristol Myers Squibb. These existing medications are frequently employed off-label to manage psychosis in patients with Alzheimer's, despite lacking formal approval for such use.

Alzheimer's agitation, impacting 60% to 70% of patients, is another significant focus for Cobenfy. Bristol Myers Squibb's Chief Commercialization Officer, Adam Lenkowsky, highlighted that Cobenfy might be the pioneering drug specifically sanctioned for Alzheimer's-related psychosis.

Anticipation builds as the pharmaceutical company plans to unveil initial late-stage trial data for the treatment of Alzheimer's-related psychosis using Cobenfy later this year. Trials focusing on Alzheimer's agitation, cognition, and bipolar disorder are slated for 2025, with autism studies commencing in 2026.

Industry observers project substantial financial success for Cobenfy, with JPMorgan analyst Chris Schott forecasting sales to ascend to $5 billion by 2030, reaching a potential peak of $10 billion across multiple treatment uses. This boon is crucial for Bristol Myers Squibb, addressing the looming issue of revenue shortfalls tied to patent expirations on top-selling medications.

Marking a historic milestone, Cobenfy became the first groundbreaking treatment for the 3 million U.S. adults with schizophrenia, securing approval in September after Bristol Myers Squibb's $14 billion acquisition of Karuna Therapeutics.

The creation of Cobenfy traces back to the 1990s when Eli Lilly explored using xanomeline for cognitive decline in Alzheimer's patients. Despite promising results, the treatment was held back due to severe gastrointestinal side effects. Andrew Miller, of Karuna Therapeutics, later developed a novel approach by combining xanomeline with trospium to mitigate these adverse effects, culminating in Cobenfy's development.

As new Alzheimer's treatments like Biogen's Leqembi and Eli Lilly's Kisunla focus on clearing toxic amyloid plaques, Cobenfy stands ready to fill the treatment gap for progressive symptoms like psychosis and agitation, potentially transforming the Alzheimer's care landscape. Chief Commercialization Officer Adam Lenkowsky elaborates, "If you can eliminate the psychosis, the agitation, cognitive function improves. It's a paradigm shift for caregivers and the healthcare system."

Source: IndexBox Market Intelligence Platform

This report provides an in-depth analysis of the pharmaceutical preparation market in the U.S.. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2030.

Product coverage:

  • NAICS 325412 - Pharmaceutical preparation manufacturing

Companies mentioned:

  • Pfizer Inc.
  • Merck & Co.
  • Abbott Laboratories
  • Abbvie Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Genentech
  • Baxter International
  • Allergan
  • Biogen, Glaxosmithkline
  • Celgene Corporation
  • Hospira
  • Alere
  • Perrigo Company
  • Mylan Inc.
  • Regeneron Pharmaceuticals
  • Novartis Corporation
  • Alexion Pharmaceuticals
  • Genzyme Corporation
  • Zoetis
  • Sanofi US Services
  • Olympus Partners
  • Valeant Pharmaceuticals International
  • Merck Sharp & Dohme Corp.
  • Glaxosmithkline Holdings (Americas)
  • Wyeth
  • Astrazeneca Pharmaceuticals
  • Actavis Inc.
  • Alcon Laboratories Holding Corporation
  • Roche Holdings

Country coverage:

  • United States

Data coverage:

  • Market volume and value
  • Per Capita consumption
  • Forecast of the market dynamics in the medium term
  • Trade (exports and imports) in the U.S.
  • Export and import prices
  • Market trends, drivers and restraints
  • Key market players and their profiles

Reasons to buy this report:

  • Take advantage of the latest data
  • Find deeper insights into current market developments
  • Discover vital success factors affecting the market

This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.

In this report, you can find information that helps you to make informed decisions on the following issues:

  1. How to diversify your business and benefit from new market opportunities
  2. How to load your idle production capacity
  3. How to boost your sales on overseas markets
  4. How to increase your profit margins
  5. How to make your supply chain more sustainable
  6. How to reduce your production and supply chain costs
  7. How to outsource production to other countries
  8. How to prepare your business for global expansion

While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.

  1. 1. INTRODUCTION

    Making Data-Driven Decisions to Grow Your Business

    1. REPORT DESCRIPTION
    2. RESEARCH METHODOLOGY AND AI PLATFORM
    3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
    4. GLOSSARY AND SPECIFIC TERMS

  2. 2. EXECUTIVE SUMMARY

    A Quick Overview of Market Performance

    1. KEY FINDINGS
    2. MARKET TRENDS This Chapter is Available Only for the Professional Edition PRO

  3. 3. MARKET OVERVIEW

    Understanding the Current State of The Market and Its Prospects

    1. MARKET SIZE
    2. MARKET STRUCTURE
    3. TRADE BALANCE
    4. PER CAPITA CONSUMPTION
    5. MARKET FORECAST TO 2030

  4. 4. MOST PROMISING PRODUCT

    Finding New Products to Diversify Your Business

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
    2. BEST-SELLING PRODUCTS
    3. MOST CONSUMED PRODUCT
    4. MOST TRADED PRODUCT
    5. MOST PROFITABLE PRODUCT FOR EXPORT

  5. 5. MOST PROMISING SUPPLYING COUNTRIES

    Choosing the Best Countries to Establish Your Sustainable Supply Chain

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
    2. TOP PRODUCING COUNTRIES
    3. TOP EXPORTING COUNTRIES
    4. LOW-COST EXPORTING COUNTRIES

  6. 6. MOST PROMISING OVERSEAS MARKETS

    Choosing the Best Countries to Boost Your Exports

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
    2. TOP CONSUMING MARKETS
    3. UNSATURATED MARKETS
    4. TOP IMPORTING MARKETS
    5. MOST PROFITABLE MARKETS

  7. 7. PRODUCTION

    The Latest Trends and Insights into The Industry

    1. PRODUCTION VOLUME AND VALUE

  8. 8. IMPORTS

    The Largest Import Supplying Countries

    1. IMPORTS FROM 2012–2024
    2. IMPORTS BY COUNTRY
    3. IMPORT PRICES BY COUNTRY

  9. 9. EXPORTS

    The Largest Destinations for Exports

    1. EXPORTS FROM 2012–2024
    2. EXPORTS BY COUNTRY
    3. EXPORT PRICES BY COUNTRY

  10. 10. PROFILES OF MAJOR PRODUCERS

    The Largest Producers on The Market and Their Profiles

    This Chapter is Available Only for the Professional Edition PRO

  11. LIST OF TABLES

    1. Key Findings In 2024
    2. Market Volume, In Physical Terms, 2012–2024
    3. Market Value, 2012–2024
    4. Per Capita Consumption In 2012-2024
    5. Imports, In Physical Terms, By Country, 2012–2024
    6. Imports, In Value Terms, By Country, 2012–2024
    7. Import Prices, By Country Of Origin, 2012–2024
    8. Exports, In Physical Terms, By Country, 2012–2024
    9. Exports, In Value Terms, By Country, 2012–2024
    10. Export Prices, By Country Of Destination, 2012–2024

  12. LIST OF FIGURES

    1. Market Volume, In Physical Terms, 2012–2024
    2. Market Value, 2012–2024
    3. Market Structure – Domestic Supply vs. Imports, In Physical Terms, 2012-2024
    4. Market Structure – Domestic Supply vs. Imports, In Value Terms, 2012-2024
    5. Trade Balance, In Physical Terms, 2012-2024
    6. Trade Balance, In Value Terms, 2012-2024
    7. Per Capita Consumption, 2012-2024
    8. Market Volume Forecast to 2030
    9. Market Value Forecast to 2030
    10. Products: Market Size And Growth, By Type
    11. Products: Average Per Capita Consumption, By Type
    12. Products: Exports And Growth, By Type
    13. Products: Export Prices And Growth, By Type
    14. Production Volume And Growth
    15. Exports And Growth
    16. Export Prices And Growth
    17. Market Size And Growth
    18. Per Capita Consumption
    19. Imports And Growth
    20. Import Prices
    21. Production, In Physical Terms, 2012–2024
    22. Production, In Value Terms, 2012–2024
    23. Imports, In Physical Terms, 2012–2024
    24. Imports, In Value Terms, 2012–2024
    25. Imports, In Physical Terms, By Country, 2024
    26. Imports, In Physical Terms, By Country, 2012–2024
    27. Imports, In Value Terms, By Country, 2012–2024
    28. Import Prices, By Country Of Origin, 2012–2024
    29. Exports, In Physical Terms, 2012–2024
    30. Exports, In Value Terms, 2012–2024
    31. Exports, In Physical Terms, By Country, 2024
    32. Exports, In Physical Terms, By Country, 2012–2024
    33. Exports, In Value Terms, By Country, 2012–2024
    34. Export Prices, By Country Of Destination, 2012–2024

Recommended posts

Free Data: Pharmaceutical Preparation - United States
Table
Pharmaceutical Preparation - United States - Table
Dashboard
Pharmaceutical Preparation - United States - Dashboard
Report
Pharmaceutical Preparation - United States - Report